Daiichi Sankyo, Inc.
Bernards, NJ Doing business as Daiichi Pharmaceutical Corp
- UEI
- YUKQY5G72Q29
- CAGE
- 1SZB9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 211 Mt Airy Rd, Basking Ridge, NJ 07920, USA
- Website
- daiichisankyo.com
- Founded
- 2005
- Employees
- 10K-50K
- Estimated annual revenue
- $250M-$500M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Turalio 125MG, 120CT | Federal Medical Center Carswell | $22,725 | |
| Turalio 125MG, 120CT | Federal Medical Center Carswell | $22,725 | |
| Turalio 125MG, 120CT | Federal Medical Center Carswell | $22,725 | |
| Turalio 125MG, 120CT, oral | Federal Medical Center Carswell | $22,725 | |
| FY26 APR turalio daiichi pharmacy/biologics order | Federal Medical Center Carswell | $22,725 |
About Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., doing business as Daiichi Pharmaceutical Corp, manufactures and supplies specialty pharmaceuticals to federal agencies as a prime contractor under full-and-open competition on the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB), with no subcontract footprint and no use of socioeconomic set-asides. The for-profit pharmaceutical manufacturer, headquartered in Basking Ridge, New Jersey, competes exclusively on unrestricted awards, not set-asides.
Daiichi Sankyo's federal capability portfolio consists entirely of TURALIO (pexidartinib), a specialty medication indicated for treatment of tenosynovial giant cell tumor, a rare musculoskeletal condition. The company holds a single-award Blanket Purchase Agreement with the VA National Acquisition Center valued at $80,206.95, effective May 22, 2025, through May 21, 2027, with four optional one-year renewal periods, authorizing Veterans Integrated Service Networks 20 and 22 to place delivery orders on an as-needed basis in both 125-milligram and 200-milligram capsule formulations. Representative delivery orders from the past two years include a $208,538.07 order from VISN 20 awarded October 1, 2025; a $73,651.68 order from VISN 20 awarded July 20, 2024; and recurring monthly orders from Federal Medical Center Carswell, a civilian facility within the Bureau of Prisons, each valued at approximately $22,000–$22,700, issued against the BPA structure and placed between February and July 2026.
Customer concentration is heavily skewed to Veterans Affairs. The top five customer entities account for 100% of awards by count. VISN 12 dominates potential value at $611.9 million across two awards, though those awards carry zero or near-zero obligated dollars and appear to represent framework or ceiling orders rather than executed delivery volume. The Department of Veterans Affairs National Acquisition Center (the BPA holder) accounts for $1.5 million potential value across two awards, while VISN 20 has issued six awards totaling $240 thousand and Federal Medical Center Carswell has issued nine awards totaling $203 thousand in actual delivery orders placed against the BPA. VISN 22 rounds out the active set with three awards worth $30 thousand. Real obligated dollars across all awards total $472 thousand, reflecting the distinction between BPA ceilings and actual delivery volume.
The company places work exclusively under the GSA Pharmaceuticals and Drugs Schedule, with twenty task orders totaling $1.9 million in combined potential value. NAICS concentration is absolute: all twenty-two awards fall under Pharmaceutical Preparation Manufacturing. PSC coding splits between Drugs And Biologicals (thirteen awards) and Pharmacy Services (nine awards).
Activity has grown sharply in 2025 and 2026, rising from one award in 2022 to six awards per year in both 2025 and 2026, reflecting expanded ordering against the newly established May 2025 BPA. Two awards with ultimate completion dates in the next twenty-four months carry combined potential value of $23 thousand and face recompete exposure, though the structure suggests routine renewal rather than competitive recompete risk given the single-award BPA framework and Daiichi Sankyo's exclusive position as the supplier of record for TURALIO within the VA system.
Contract vehicles
Quick answers
What is Daiichi Sankyo, Inc.'s UEI?
Daiichi Sankyo, Inc.'s Unique Entity ID (UEI) in SAM.gov is YUKQY5G72Q29.
What is Daiichi Sankyo, Inc.'s CAGE code?
Daiichi Sankyo, Inc.'s CAGE code is 1SZB9.
What is Daiichi Sankyo, Inc.'s primary NAICS code?
Daiichi Sankyo, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Daiichi Sankyo, Inc. located?
Daiichi Sankyo, Inc.'s physical address in SAM.gov is 211 Mt Airy Rd, Basking Ridge, NJ 07920, USA.
Is Daiichi Sankyo, Inc. registered in SAM.gov?
Yes. Daiichi Sankyo, Inc.'s SAM.gov registration is active through December 1, 2026.
Which contract vehicles does Daiichi Sankyo, Inc. hold?
Daiichi Sankyo, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Daiichi Sankyo, Inc.'s most recent federal award?
Daiichi Sankyo, Inc.'s most recent federal contract award is Turalio 125MG, 120CT (15B50526F00000183), from Federal Medical Center Carswell, on September 30, 2026.
On GovTribe
See Daiichi Sankyo, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors